Pioneers in Neuroscience

2021 Year in Review

As a purpose-driven company, we seek ways to reinforce our commitment to climate, health and equity. Our 2021 Year in Review reports on our progress on these and other priorities to create a healthier, more equitable and sustainable world. 

Behind the medicine cabinet – the multiple modality approach

Drug developers are reaching into an expanding toolbox of modalities that allow them to address any facet of a disease. With the advent of new technologies that target disease causing proteins, DNA or RNA, scientists have the potential to single out and correct problem areas within our biology. With this backdrop of possibilities, Anabella Villalobos, Head of Biotherapeutics and Medicinal Sciences (BTMS) at Biogen, and her team are finding ways to give people living with neurological diseases options.

Amyotrophic Lateral Sclerosis (ALS) at Biogen

We aspire to improve the lives of people living with and caring for those with ALS.

Biogen Digital Health

Biogen Digital Health aspires to transform patients’ lives and Biogen by making personalized & digital medicine in neuroscience a reality.

SOD1-ALS: Tofersen Early Access Program (EAP)
5/9/22 7:30 PM EDT
EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE  UNDER THE ACCELERATED APPROVAL PATHWAY
View all news
Biogen updates delivered to your inbox
Diversity, Equity and Inclusion

Biogen is committed to the power of diversity – in our organization and among our patients and customers. Diversity is an essential asset of complementary strengths and perspectives from which all benefit, and which must unite us, not divide us.

Where Science Meets Humanity

Science that transforms patient lives. Science that seeks to solve societal problems. Science that acts with purpose. Science that is inspired by the diversity and passion of our people. Discover where science meets humanity at Biogen.

Follow us on social media